Details of the Drug

General Information of Drug (ID: DMMOFHT)

Drug Name

Pirprofen

Synonyms

Pirprofen; Rengasil; 31793-07-4; Pirprofenum [INN-Latin]; Pirprofene [INN-French]; Pirprofeno [INN-Spanish]; SU-21524; EINECS 250-805-8; BRN 1686438; SU 21524; Hydratropic acid, 3-chloro-4-(3-pyrrolin-1-yl)-; 3-CHLORO-4-(3-PYRROLIN-1-YL)HYDRATROPIC ACID; C13H14ClNO2; Pirprofenum; Pirprofeno; Pirprofene; Benzeneacetic acid, 3-chloro-4-(2,5-dihydro-1H-pyrrol-1-yl)-alpha-methyl-; Pirprofen [USAN:INN:BAN]; Pirprofen [USAN:BAN:INN]; pirprofen[usan:ban:inn]; Pirprofen (USAN/INN); AC1Q5RRJ; AC1L1UQD; SCHEMBL24311; 5-20-04-00276 (Beilstei

Indication

Disease Entry	ICD 11	Status	REF
Dysmenorrhea	GA34.3	Approved	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

251.71

Logarithm of the Partition Coefficient (xlogp)

2.9

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 45.4 micromolar/kg/day [3]

Chemical Identifiers

Formula: C13H14ClNO2
IUPAC Name: 2-[3-chloro-4-(2,5-dihydropyrrol-1-yl)phenyl]propanoic acid
Canonical SMILES: CC(C1=CC(=C(C=C1)N2CC=CC2)Cl)C(=O)O
InChI: InChI=1S/C13H14ClNO2/c1-9(13(16)17)10-4-5-12(11(14)8-10)15-6-2-3-7-15/h2-5,8-9H,6-7H2,1H3,(H,16,17)
InChIKey: PIDSZXPFGCURGN-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 35935
ChEBI ID: CHEBI:135028
CAS Number: 31793-07-4
DrugBank ID: DB13722
TTD ID: D0S9ET
INTEDE ID: DR1304

Molecular Interaction Atlas of This Drug

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
UDP-glucuronosyltransferase 1A1 (UGT1A1)_{Main DME}	DEYGVN4	UD11_HUMAN	Substrate	[4]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Antileukoproteinase (SLPI)	OTUNFUU8	SLPI_HUMAN	Gene/Protein Processing	[5]
Bone morphogenetic protein 6 (BMP6)	OT9WN536	BMP6_HUMAN	Gene/Protein Processing	[5]
Hepatocyte growth factor receptor (MET)	OT7K55MU	MET_HUMAN	Gene/Protein Processing	[5]
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Gene/Protein Processing	[5]
Interleukin-24 (IL24)	OT4VUWH1	IL24_HUMAN	Gene/Protein Processing	[5]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Gene/Protein Processing	[5]
Proepiregulin (EREG)	OTRM4NQY	EREG_HUMAN	Gene/Protein Processing	[5]
PTB-containing, cubilin and LRP1-interacting protein (PID1)	OT5YJ7FI	PCLI1_HUMAN	Gene/Protein Processing	[5]
Tumor necrosis factor-inducible gene 6 protein (TNFAIP6)	OT1SLUZH	TSG6_HUMAN	Gene/Protein Processing	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
3	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
4	Glucuronidation of 2-arylpropionic acids pirprofen, flurbiprofen, and ibuprofen by liver microsomes. Drug Metab Dispos. 1990 Sep-Oct;18(5):692-7.
5	An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.